ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Allakos Inc

Allakos Inc (ALLK)

1.42
0.12
(9.23%)
Closed May 27 4:00PM
1.45
0.03
(2.11%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.42
Bid
1.18
Ask
1.70
Volume
731,075
1.26 Day's Range 1.45
0.9799 52 Week Range 5.64
Market Cap
Previous Close
1.30
Open
1.33
Last Trade
1
@
1.33
Last Trade Time
Financial Volume
$ 995,957
VWAP
1.3623
Average Volume (3m)
510,403
Shares Outstanding
87,873,995
Dividend Yield
-
PE Ratio
-0.68
Earnings Per Share (EPS)
-2.11
Revenue
-
Net Profit
-185.7M

About Allakos Inc

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Allakos Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALLK. The last closing price for Allakos was $1.30. Over the last year, Allakos shares have traded in a share price range of $ 0.9799 to $ 5.64.

Allakos currently has 87,873,995 shares outstanding. The market capitalization of Allakos is $125.66 million. Allakos has a price to earnings ratio (PE ratio) of -0.68.

ALLK Latest News

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.6993006993011.431.511.263911811.40405879CS
40.3937.86407766991.031.510.98074649621.26257191CS
12-0.06-4.054054054051.481.690.97995104031.26786062CS
26-0.33-18.85714285711.753.4050.979911222361.65216579CS
52-3.52-71.25506072874.945.640.979910533272.4615706CS
156-101.12-98.615174566102.54112.870.979913249209.0961088CS
260-42.44-96.762425900643.86157.980.979993318020.33476338CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

ALLK Discussion

View Posts
Monksdream Monksdream 2 months ago
ALLK 10Q due 3/19
👍️0
Monksdream Monksdream 2 months ago
ALLK under $2
👍️0
Monksdream Monksdream 3 months ago
ALLK 10Q due March 12
👍️0
Monksdream Monksdream 3 months ago
ALLK 10Q due March 5
👍️0
glenn1919 glenn1919 3 months ago
ALLK..........................................................................https://stockcharts.com/h-sc/ui?s=ALLK&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
ALLK under $2
👍️0
RobH1312 RobH1312 2 years ago
THIS POS IS A SCAM GONNA GO DOWN DOWN DOWN!!!

















imo
👍️0
REAGAN REAGAN 2 years ago
We will go short on this one.
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Agree, the next couple weeks should be very interesting .
👍️0
REAGAN REAGAN 2 years ago
The whole Nasdaq is crashing. A stock whose IP doesn’t work should be pulverized next week.
👍️0
REAGAN REAGAN 2 years ago
Made it go down 95%. The technology doesn’t work….
👍️0
FROZENFLAME FROZENFLAME 2 years ago
It was a good flip, still looks attractive at this level, but I will wait .
👍️0
REAGAN REAGAN 2 years ago
This aged well
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis (EoE). Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints.
“We are deeply disappointed that the studies did not achieve their symptomatic endpoints,” said Robert Alexander, PhD, Chief Executive Officer of Allakos. “The company is grateful to the patients with eosinophilic gastrointestinal diseases (EGIDs) and to the investigators who participated in the ENIGMA and KRYPTOS trials.”
👍️0
REAGAN REAGAN 2 years ago
Zero squeeeze. What’s up with this company. How’d it lose 97% of value in one year?
👍️0
REAGAN REAGAN 2 years ago
So what’s the deal with this stock? Why has the stock price fallen 97%? Where do you see the company has $500m cash on hand?
👍️0
BullofLA BullofLA 2 years ago
Yup, total scam, run away.
👍️0
Inves2day Inves2day 2 years ago
Allakos holders - please read and share the link below.


Stock wash sale 30 days period ended on 21 January 2022. December sellers will be looking to buy back now. Two after hours buys yesterday make more sense now.

ALLK is a forgotten share, but not for those who have to buy it back. The seller is gone for two days, but the sentiment is negative around all Nasdaq shares hence negative ends on Thu and Fr. This will change too.
I saw on Thursday 20 January that there was an appetite to climb up, really. Virtually no seller around. During the day all was going well, MMs were ticking it nicely higher until that moment of crash caused by Netflix followed by the entire Nasdaq falling down. Friday Nasdaq still down so ALLK too. But every crash ends and reversal starts for new buyers.

Look, as ALLK holders, we all can and have to create a need for shorters and those who sold in December for tax reasons to start the buy back. We need an bigger action to close day at 5-10% up to get noticed in media.
I. e. ADGI reversed exactly after 30 days wash sale. Allakos can do the same if we really want it.

Sell only if you really have to or Hold it for a few more days to see if recovery kicks in with Nasdaq stabilising.

Allakos Inc at $7 mcap is slightly lower than cash and equivalents.
We know they did not deliver but ffs share is down from $84 to $7 and they still be looking to use thst drug in another areas.

Please share the below post on Twitter for awareness.

https://twitter.com/inves2day/status/1485023226753437698?t=aK2TQngCviUwopFKMOEmjQ&s=19


Thank you for reading and sharing.

*23 Jan - my account on StockTwits has been suspended after posting the above link*
👍️0
Banjo50 Banjo50 2 years ago
IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!
👍️0
donwillems donwillems 2 years ago
well this has 3 stages for me, everything +9.50, allright
everything above 10+, superb
everything above 12.50, winner winner chicken dinner.

A company with 500 million up their sleeves, I think they might figure something out.

And whats more, why did I buy into this company?
I have EOE myself, it's being triggered by cow milk with me and my throat and stumach gets hurt really bad by the eosiphiniles If I don't watch out with avoiding everything with milk.

I'm totally wondered here how that however the drug significantly reducing the eosiphiniles in situ doesn't get a response on the symptons, this starts me wondering if the direct symptons only thrive by the (food)allergy people have with it.

For now, I avoid milk and use omeprazole to completly suppres the effects, corticosteriod can be used locally but they are bad for blood vessels long term.

To get to the point, I think this drug isn't wrote off at all, the eosiphiniles do damage the throat a lot long term in this disease, if left untreathed, the throat will start forming circular scars, making it smaller and making it long term impossible to get food into the stumach.

The research completly ignores this problem, while it's the second main cause for treating this disease, unimaginable if you ask me.
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Sure she’s trying to breakout !
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Squeeze !
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Dip and rip, short trying so hard !!
👍️0
da_stock_analyst da_stock_analyst 2 years ago
Two Stocks to Watch: #NXTD ?? #ALLK ?? Should you buy now for the possible run-up? Technical analysis!
👍️0
Huti Huti 2 years ago
20??? Maybe??? What do you guys think?
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
DD here Can someone Box/Sticky it
$ALLK($9.55) well.... they are buying ... follow the big money pic.twitter.com/ktNzM7e3RS— World News (@tryingBot05) December 23, 2021
https://twitter.com/RealTimeTradez/status/1473987872197914633/photo/1
https://twitter.com/SilentTrader93/status/1474112595133177859
https://twitter.com/RealTimeTradez/status/1473809286354583557
https://twitter.com/RealTimeTradez/status/1474081174448398343
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
ALLK New Patient Dec.21 2021
https://twitter.com/RealTimeTradez/status/1473987872197914633/photo/1
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
https://twitter.com/SilentTrader93/status/1474112595133177859/photo/1
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
https://twitter.com/RealTimeTradez/status/1473809286354583557/photo/1
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
https://twitter.com/RealTimeTradez/status/1474081174448398343/photo/1
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
https://twitter.com/tryingBot05/status/1473861479309152257/photo/1
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Next week should be sooo good IMO .
👍️0
Laszlo1 Laszlo1 2 years ago
Took a starter
👍️0
forgiveness7x7 forgiveness7x7 2 years ago
that's what i'm here scouting out. looks like analysts have different opinions on price. from 10.00 to 60.00
i think it is a short attack and whatever else
👍️0
Laszlo1 Laszlo1 2 years ago
What happened here what causes the huge drop?
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Huge volume over 63M $$$
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Agree, a little bit more Consolidations, before the next leg up, then BOOOOM .
👍️0
alchemytrader alchemytrader 2 years ago
10.79
👍️0
Justfactsmam Justfactsmam 2 years ago
looks like the Short Squeeze commencing!
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Very small SS short squeeze will take it to the moon .
👍️0
FROZENFLAME FROZENFLAME 2 years ago
I’m good with $50 lol .
👍️0
sirglenn sirglenn 2 years ago
Maybe they'll buy their own stock. LOL.
👍️0
Justfactsmam Justfactsmam 2 years ago
And GOLDMAN lowered the price target to $60.00...(6X) from here. Some see things others don't.
👍️0
crudeoil24 crudeoil24 2 years ago
9.91 > Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $10
All these analysts are comedians!
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Expecting $15-$20 next week .
👍️0
FROZENFLAME FROZENFLAME 2 years ago
Over $10 premarket .
👍️0
maximumgriff maximumgriff 2 years ago
It’s never too late :)
👍️0
Tom turtles Tom turtles 2 years ago
Wish I was short here....holy smokes
👍️0
alchemytrader alchemytrader 2 years ago
500 mill cash on hand?


they burn 50 mill a quarter.
👍️0
alchemytrader alchemytrader 2 years ago
we will...but if it doesnt happen tomorrow then the a/h buyers will head towards the exits and this is at 7.00.
👍️0

Your Recent History

Delayed Upgrade Clock